Definium Therapeutics (NASDAQ:DFTX) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Definium Therapeutics (NASDAQ:DFTX – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, October 15th. Wells Fargo & Company upped their price objective on Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Maxim Group set a $55.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research report on Friday, August 14th. Canaccord Genuity Group set a $78.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. Finally, Piper Sandler restated an “overweight” rating and issued a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.24.

Check Out Our Latest Analysis on Definium Therapeutics

Definium Therapeutics Price Performance

Shares of Definium Therapeutics stock traded down $0.92 on Friday, hitting $32.08. 777,628 shares of the company traded hands, compared to its average volume of 1,700,770. Definium Therapeutics has a 12-month low of $10.46 and a 12-month high of $49.70. The company has a current ratio of 15.53, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The company has a market cap of $4.31 billion, a P/E ratio of -10.32 and a beta of 2.23. The firm’s 50-day simple moving average is $36.07 and its 200 day simple moving average is $30.38.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.09. Analysts expect that Definium Therapeutics will post -2.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In other news, insider Mark Sullivan sold 14,051 shares of the firm’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the transaction, the insider directly owned 494,228 shares of the company’s stock, valued at approximately $18,073,917.96. This trade represents a 2.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $1,153,783.50. Following the transaction, the chief executive officer directly owned 2,213,090 shares in the company, valued at $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 71,098 shares of company stock valued at $2,626,115. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pinnacle Wealth Planning Services Inc. lifted its position in Definium Therapeutics by 2,928.0% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company’s stock valued at $29,000 after purchasing an additional 732 shares during the last quarter. Nykredit A S bought a new position in shares of Definium Therapeutics in the second quarter worth approximately $45,000. Bessemer Group Inc. bought a new position in shares of Definium Therapeutics in the third quarter worth approximately $42,000. GAMMA Investing LLC increased its stake in shares of Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock worth $59,000 after buying an additional 343 shares during the period. Finally, Allworth Financial LP purchased a new position in shares of Definium Therapeutics in the second quarter worth $110,000. 27.91% of the stock is currently owned by institutional investors.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

Further Reading

Analyst Recommendations for Definium Therapeutics (NASDAQ:DFTX)

Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.